201 related articles for article (PubMed ID: 25510278)
41. Phospho-CRKL monitoring for the assessment of BCR-ABL activity in imatinib-resistant chronic myeloid leukemia or Ph+ acute lymphoblastic leukemia patients treated with nilotinib.
La Rosée P; Holm-Eriksen S; Konig H; Härtel N; Ernst T; Debatin J; Mueller MC; Erben P; Binckebanck A; Wunderle L; Shou Y; Dugan M; Hehlmann R; Ottmann OG; Hochhaus A
Haematologica; 2008 May; 93(5):765-9. PubMed ID: 18367481
[TBL] [Abstract][Full Text] [Related]
42. Synergism between bosutinib (SKI-606) and the Chk1 inhibitor (PF-00477736) in highly imatinib-resistant BCR/ABL⁺ leukemia cells.
Nguyen T; Hawkins E; Kolluri A; Kmieciak M; Park H; Lin H; Grant S
Leuk Res; 2015 Jan; 39(1):65-71. PubMed ID: 25465126
[TBL] [Abstract][Full Text] [Related]
43. The src homology 2 domain of Bcr/Abl is required for efficient induction of chronic myeloid leukemia-like disease in mice but not for lymphoid leukemogenesis or activation of phosphatidylinositol 3-kinase.
Roumiantsev S; de Aos IE; Varticovski L; Ilaria RL; Van Etten RA
Blood; 2001 Jan; 97(1):4-13. PubMed ID: 11133737
[TBL] [Abstract][Full Text] [Related]
44. Targeting STAT5 or STAT5-Regulated Pathways Suppresses Leukemogenesis of Ph+ Acute Lymphoblastic Leukemia.
Minieri V; De Dominici M; Porazzi P; Mariani SA; Spinelli O; Rambaldi A; Peterson LF; Porcu P; Nevalainen MT; Calabretta B
Cancer Res; 2018 Oct; 78(20):5793-5807. PubMed ID: 30154155
[TBL] [Abstract][Full Text] [Related]
45. Preclinical and clinical efficacy of XPO1/CRM1 inhibition by the karyopherin inhibitor KPT-330 in Ph+ leukemias.
Walker CJ; Oaks JJ; Santhanam R; Neviani P; Harb JG; Ferenchak G; Ellis JJ; Landesman Y; Eisfeld AK; Gabrail NY; Smith CL; Caligiuri MA; Hokland P; Roy DC; Reid A; Milojkovic D; Goldman JM; Apperley J; Garzon R; Marcucci G; Shacham S; Kauffman MG; Perrotti D
Blood; 2013 Oct; 122(17):3034-44. PubMed ID: 23970380
[TBL] [Abstract][Full Text] [Related]
46. Crizotinib acts as ABL1 inhibitor combining ATP-binding with allosteric inhibition and is active against native BCR-ABL1 and its resistance and compound mutants BCR-ABL1
Mian AA; Haberbosch I; Khamaisie H; Agbarya A; Pietsch L; Eshel E; Najib D; Chiriches C; Ottmann OG; Hantschel O; Biondi RM; Ruthardt M; Mahajna J
Ann Hematol; 2021 Aug; 100(8):2023-2029. PubMed ID: 34110462
[TBL] [Abstract][Full Text] [Related]
47. Reprogramming of primary human Philadelphia chromosome-positive B cell acute lymphoblastic leukemia cells into nonleukemic macrophages.
McClellan JS; Dove C; Gentles AJ; Ryan CE; Majeti R
Proc Natl Acad Sci U S A; 2015 Mar; 112(13):4074-9. PubMed ID: 25775523
[TBL] [Abstract][Full Text] [Related]
48. Chemotherapeutic agents circumvent emergence of dasatinib-resistant BCR-ABL kinase mutations in a precise mouse model of Philadelphia chromosome-positive acute lymphoblastic leukemia.
Boulos N; Mulder HL; Calabrese CR; Morrison JB; Rehg JE; Relling MV; Sherr CJ; Williams RT
Blood; 2011 Mar; 117(13):3585-95. PubMed ID: 21263154
[TBL] [Abstract][Full Text] [Related]
49. Clinical significance of the BCR-ABL fusion gene in adult acute lymphoblastic leukemia: a Cancer and Leukemia Group B Study (8762).
Westbrook CA; Hooberman AL; Spino C; Dodge RK; Larson RA; Davey F; Wurster-Hill DH; Sobol RE; Schiffer C; Bloomfield CD
Blood; 1992 Dec; 80(12):2983-90. PubMed ID: 1467514
[TBL] [Abstract][Full Text] [Related]
50. Transcriptomic classes of BCR-ABL1 lymphoblastic leukemia.
Kim JC; Chan-Seng-Yue M; Ge S; Zeng AGX; Ng K; Gan OI; Garcia-Prat L; Flores-Figueroa E; Woo T; Zhang AXW; Arruda A; Chithambaram S; Dobson SM; Khoo A; Khan S; Ibrahimova N; George A; Tierens A; Hitzler J; Kislinger T; Dick JE; McPherson JD; Minden MD; Notta F
Nat Genet; 2023 Jul; 55(7):1186-1197. PubMed ID: 37337105
[TBL] [Abstract][Full Text] [Related]
51. Targeting signaling pathways in acute lymphoblastic leukemia: new insights.
Harrison CJ
Hematology Am Soc Hematol Educ Program; 2013; 2013():118-25. PubMed ID: 24319172
[TBL] [Abstract][Full Text] [Related]
52. BCR/ABL1-like acute lymphoblastic leukemia: How to diagnose and treat?
Chiaretti S; Messina M; Foà R
Cancer; 2019 Jan; 125(2):194-204. PubMed ID: 30561755
[TBL] [Abstract][Full Text] [Related]
53. Combination therapy of BCR-ABL-positive B cell acute lymphoblastic leukemia by tyrosine kinase inhibitor dasatinib and c-JUN N-terminal kinase inhibition.
Xiao X; Liu P; Li D; Xia Z; Wang P; Zhang X; Liu M; Liao L; Jiao B; Ren R
J Hematol Oncol; 2020 Jun; 13(1):80. PubMed ID: 32552902
[TBL] [Abstract][Full Text] [Related]
54. Expression profiling of adult acute lymphoblastic leukemia identifies a BCR-ABL1-like subgroup characterized by high non-response and relapse rates.
Boer JM; Koenders JE; van der Holt B; Exalto C; Sanders MA; Cornelissen JJ; Valk PJ; den Boer ML; Rijneveld AW
Haematologica; 2015 Jul; 100(7):e261-4. PubMed ID: 25769542
[No Abstract] [Full Text] [Related]
55. Breakpoint cluster region-c-abl oncogene 1, non-receptor tyrosine kinase signaling: current patterns of the versatile regulator revisited.
Rana A; Ali GM; Ali S; Khan A; Sabiha B; Malik S; Riaz AM; Farooqi AA
J Cancer Res Ther; 2013; 9(1):3-5. PubMed ID: 23575065
[TBL] [Abstract][Full Text] [Related]
56. Tyrosine kinase fusion genes in pediatric BCR-ABL1-like acute lymphoblastic leukemia.
Boer JM; Steeghs EM; Marchante JR; Boeree A; Beaudoin JJ; Beverloo HB; Kuiper RP; Escherich G; van der Velden VH; van der Schoot CE; de Groot-Kruseman HA; Pieters R; den Boer ML
Oncotarget; 2017 Jan; 8(3):4618-4628. PubMed ID: 27894077
[TBL] [Abstract][Full Text] [Related]
57. BCR::ABL1 tyrosine kinase inhibitors hamper the therapeutic efficacy of blinatumomab in vitro.
Kauer J; Märklin M; Pflügler M; Hörner S; Hinterleitner C; Tandler C; Jung G; Salih HR; Heitmann JS
J Cancer Res Clin Oncol; 2022 Oct; 148(10):2759-2771. PubMed ID: 35551463
[TBL] [Abstract][Full Text] [Related]
58. Mucin 4 protein is expressed in B-acute lymphoblastic leukemia and is restricted to BCR::ABL1-positive and BCR::ABL-like subtypes.
Gestrich CK; De Lancy SJ; Kresak A; Sinno MG; Yalley A; Pateva I; Meyerson H; Shetty S; Oduro KA
Hum Pathol; 2023 Jun; 136():75-83. PubMed ID: 37023866
[TBL] [Abstract][Full Text] [Related]
59. The BCR-ABL/NF-κB signal transduction network: a long lasting relationship in Philadelphia positive Leukemias.
Carrà G; Torti D; Crivellaro S; Panuzzo C; Taulli R; Cilloni D; Guerrasio A; Saglio G; Morotti A
Oncotarget; 2016 Oct; 7(40):66287-66298. PubMed ID: 27563822
[TBL] [Abstract][Full Text] [Related]
60. RUNX1 transactivates BCR-ABL1 expression in Philadelphia chromosome positive acute lymphoblastic leukemia.
Masuda T; Maeda S; Shimada S; Sakuramoto N; Morita K; Koyama A; Suzuki K; Mitsuda Y; Matsuo H; Kubota H; Kato I; Tanaka K; Takita J; Hirata M; Kataoka TR; Nakahata T; Adachi S; Hirai H; Mizuta S; Naka K; Imai Y; Kimura S; Sugiyama H; Kamikubo Y
Cancer Sci; 2022 Feb; 113(2):529-539. PubMed ID: 34902205
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
